8-K Announcements
6Material company update
May 4, 2026·SEC
Material company update
Mar 11, 2026·SEC
Material company update
Mar 2, 2026·SEC
CNS Pharmaceuticals, Inc.(CNSP)Earnings, Financials & Key Ratios
CNSP•NASDAQ
$3.98
Price updated Jun 27, 2026
AboutCNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, an anthracycline that is in Phase I and II clinical trials that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc. and The University of Texas M.D. Anderson Cancer Center, as well as Animal Life Sciences, LLC; and a development agreement with WPD Pharmaceuticals Inc., as well as a collaboration agreement with Reata Pharmaceuticals, Inc. The company was incorporated in 2017 and is based in Houston, Texas.Show more
- Revenue$0
- EBITDA-$16M-7.3%
- Net Income-$16M-6.7%
- EPS (Diluted)-35.75+92.3%
- ROE-296.3%+82.6%
CNSP Price & Volume
CNS Pharmaceuticals, Inc. (CNSP) stock price & volume — 10-year historical chart
Loading chart...
Persistent Clinical Burn Threatens Capital Structure Stability
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Mixed
Profitability:Negative
Financial Position:Vulnerable
Cash Flow:Burning
Primary Risk:Binary clinical trial outcome
"CNS Pharmaceuticals remains a high-risk, pre-revenue biotechnology entity whose valuation is entirely dependent on the success of its intangible clinical pipeline. The company faces a severe financing overhang, evidenced by a rapid contraction in total assets from $14.5 million in 2025Q2 to $4.7 million in 2026Q1. Investors should monitor the company's ability to secure non-dilutive funding, as the current trajectory of quarterly operating losses reaching $6.0 million suggests an urgent need for capital intervention to maintain operational continuity."
Verdict Logic
the company's equity base has plummeted to $70.7K as of 2026Q1, indicating extreme dilution risk and a precarious financial position for potential shareholders.
CNSP Growth Metrics
CNS Pharmaceuticals, Inc. (CNSP) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-5.58%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM99.3%
Return on Capital
10 Years-509.51%
5 Years-674.02%
3 Years-1008.94%
Last Year-298.84%
Peers Comparison
Key metrics vs top competitors for CNS Pharmaceuticals, Inc. (CNSP)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $3.98 | $2.69M | -0.11 | — | — | -296.3% | — | |
| $63.65 | $1.24B | -6.54 | -43.89% | -284.18% | -87% | — | |
| $21.31 | $1.88B | -6.48 | 627.84% | -112.01% | -256.66% | — | |
| $2.52 | $55.26M | -0.76 | — | — | -1335.64% | — | |
| $1.83 | $110.39M | -3.27 | — | — | -0% | — | |
| $37.90 | $2.25B | -5.32 | 48.03% | -639.84% | -34.11% | — |
Compare CNSP vs Peers
CNS Pharmaceuticals, Inc. (CNSP) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
CNSP SEC Filings & Documents
CNS Pharmaceuticals, Inc. (CNSP) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when CNSP posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
CNSP Frequently Asked Questions
CNS Pharmaceuticals, Inc. (CNSP) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Is CNSP profitable?
CNS Pharmaceuticals, Inc. (CNSP) reported a net loss of $16.5M for fiscal year 2025.
Dividend & Returns
What is CNSP's return on equity?
CNS Pharmaceuticals, Inc. (CNSP) has a return on equity (ROE) of -296.3%. Negative ROE indicates the company is unprofitable.
What is CNS Pharmaceuticals, Inc.'s free cash flow?
CNS Pharmaceuticals, Inc. (CNSP) had negative free cash flow of $15.2M in fiscal year 2025, likely due to heavy capital investments.